RETEVMO vs ZORTRESS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. RETEVMO and ZORTRESS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	RETEVMO	ZORTRESS
Rating	New	70/100
Pharmacy pays	—	~$229.16 /30
Type	RX	RX
Active ingredient	SELPERCATINIB	EVEROLIMUS
Manufacturer	Eli Lilly and Co	Novartis
Dosage forms	Capsule, Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Half-life	—	about 30 hours (mean terminal elimination half-life)
Treats	Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms	—

retevmo zortress

Rating

New

70/100

Pharmacy pays

—

~$229.16 /30

Type

Active ingredient

SELPERCATINIB

EVEROLIMUS

Manufacturer

Eli Lilly and Co

Novartis

Dosage forms

Capsule, Tablet

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Half-life

—

about 30 hours (mean terminal elimination half-life)

Treats

Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

—

Frequently asked questions

What is the difference between Retevmo and Zortress?

Retevmo contains Selpercatinib, while Zortress contains Everolimus — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.